Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.35 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.35 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24816262 | 0.92 | BRD4 (0.39) | CNR2CNR1TGFBR1PDE4DMAP3K14 | |
| SCHEMBL26013105 | 0.85 | CNR2 (0.39) | CNR2CNR1TGFBR1PDE4DLRRK2 | |
| SCHEMBL24007495 | 0.85 | CNR2 (0.37) | CNR2CNR1TGFBR1PDE4DLRRK2 | |
| SCHEMBL19953969 | 0.84 | TGFBR1 (0.40) | CNR2CNR1TGFBR1PDE4DKCNJ6 | |
| SCHEMBL26011688 | 0.84 | CNR2 (0.39) | CNR2CNR1TGFBR1PDE4DLRRK2 | |
| SCHEMBL24816260 | 0.80 | LRRK2 (0.38) | CNR2TGFBR1PDE4DKCNJ6KCNJ5 | |
| SCHEMBL26011686 | 0.77 | BRD4 (0.39) | CNR2CNR1LRRK2BRD4CREBBP | |
| SCHEMBL24007247 | 0.77 | BRD4 (0.39) | CNR2CNR1LRRK2BRD4CREBBP | |
| SCHEMBL24007404 | 0.77 | BRD4 (0.39) | CNR2CNR1LRRK2BRD4CREBBP | |
| SCHEMBL26012741 | 0.76 | BRD4 (0.38) | CNR2CNR1BRD4CREBBPMAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CNR2 3981/4885CNR1 4118/4885TGFBR1 3289/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | CNR2 3981/4885CNR1 4118/4885TGFBR1 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.